Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SASS 3 for Epidermolysis Bullosa
NCT04171661Phase 1Active, not recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Dec 2019
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of self-assembled skin substitute in dystrophic epidermolysis bullosa (DEB), sponsored by CHU de Québec-Université Laval. Primary endpoint: Percent reduction in wound surface area at 2 weeks. Started Dec 2019; status: active, not recruiting.
02
Drugs
self-assembled skin substitute
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT04171661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171661.